This can create dangerous gaps in care, especially for individuals managing type 2 diabetes
Not all patients respond equally to GLP-1 agonist therapy, and identifying optimal candidates requires considering multiple factors, including baseline weight, comorbidities, and individual tolerance profiles
JAMA 2021;325:1403-13.ArticlePubMed 32
8 weeks might sound like a long time, but in the grand scheme of things it really isnt
The GLP-1 era represents a fundamental shift in how consumers think about food, nutrition and wellness
People experimenting with microdosing often attribute steadier energy levels to reduced medication intensity, although experiences vary from person to person